Healthcare Industry News:  amphotericin B 

Biopharmaceuticals Regulatory

 News Release - April 4, 2006

Samaritan's Marketing Authorization Application For Amphocil Approved in Greece

LAS VEGAS--(HSMN NewsFeed)--April 4, 2006--Samaritan Pharmaceuticals, Inc. (AMEX:LIV ) is pleased to announce that its subsidiary Samaritan Pharmaceuticals Europe, S.A. has received notification by the National Pharmaceuticals Organization, (EOF) for a new marketing authorization for Amphocil in Greece.

The National Pharmaceutical Organization, (EOF), is the competent authority for granting approval to market pharmaceutical and medical products in Greece, similar to the FDA in the United States.

Samaritan Europe is currently assembling all the necessary documents to make a pricing application with the Minister of Development who issues official prices with the consent of the Minister of Health. A nine-member Pricing Committee is responsible for providing expert non-binding advice on pharmaceutical prices.

Once price approval is obtained, Samaritan will launch the product in the Greek market, thus creating a stream of revenue for the company. Dr. Christos Dakas, Managing Director for Samaritan Pharmaceuticals Europe said, "I am very pleased with the swift approval of the Marketing Authorization of Amphocil in Greece, this brings the company a step closer to the implementation of a marketing and sales infrastructure."

Samaritan established its European headquarters in Athens, Greece to allow access to the markets of East Europe, Asia and African regions with a high proportion of HIV patients, a target population for our most advanced drug SP-01A. Samaritan Pharmaceuticals Europe is currently building, a sales and marketing infrastructure to create revenue for the normally undeveloped regions of Greece, Bulgaria, Romania, Croatia, Serbia, Bosnia and Slovenia. On December 14, 2005, Samaritan In-Licensed from Three Rivers Pharmaceuticals the Greece & Cyprus Marketing Rights for Amphocil (an amphotericin B cholesteryl sulfate complex for injection indicated for the treatment of invasive aspergillosis, a fungal infection that occurs in immuno-compromised patients). Currently, Samaritan Pharmaceuticals Europe is trying to contract with other pharmaceutical companies to sell and distribute niche, high valued products in the above undeveloped European regions.

Samaritan Pharmaceuticals: "We Save Lives."

Samaritan is a small-cap Biotech, driven to discover, develop, and commercialize, innovative therapeutics' for AIDS, Alzheimer's, Cancer and Heart disease. Look at Please register on Website so we can notify you of upcoming conference calls, news and events.


The company disclaims any information that is created by an outside party and endorses only information that is communicated by its press releases, filings and Website. This news release contains forward-looking statements that reflect management's current beliefs about the potential for its drug candidates, science and technology. However, as with any biopharmaceutical under development, there are significant risks and uncertainties in the process of development and regulatory review. There are no guarantees that products will prove to be commercially successful. For additional information about the factors that affect the company's business, please read the company's latest Form 10-K filed April 15, 2005. The company undertakes no duty to update forward-looking statements.

Source: Samaritan Pharmaceuticals

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.